Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Operating Leases: 2020-2023

Historic Operating Leases for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to $4.2 million.

  • Immuneering's Operating Leases fell 6.64% to $4.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $4.2 million, marking a year-over-year decrease of 6.64%. This contributed to the annual value of $4.2 million for FY2023, which is 6.72% down from last year.
  • Per Immuneering's latest filing, its Operating Leases stood at $4.2 million for FY2023, which was down 6.72% from $4.5 million recorded in FY2022.
  • In the past 5 years, Immuneering's Operating Leases registered a high of $5.1 million during FY2021, and its lowest value of $544,767 during FY2020.
  • Moreover, its 3-year median value for Operating Leases was $4.5 million (2022), whereas its average is $4.6 million.
  • In the last 5 years, Immuneering's Operating Leases soared by 834.51% in 2021 and then fell by 12.33% in 2022.
  • Immuneering's Operating Leases (Yearly) stood at $544,767 in 2020, then spiked by 834.51% to $5.1 million in 2021, then declined by 12.33% to $4.5 million in 2022, then declined by 6.72% to $4.2 million in 2023.